Tapped as Kymab CEO, Si­mon Sturge jumps back in­to biotech pond as Dave Chiswell steps aside

Dave Chiswell is wind­ing down a leg­endary ca­reer — mark­ing a run as Cam­bridge An­ti­body Tech­nol­o­gy’s co-founder and, lat­er, CEO — by mov­ing to the back­seat at Kymab. And he’s found a fel­low vet­er­an in the UK biotech scene to hand over the ba­ton.

For Si­mon Sturge, the CEO job marks a re­turn to the en­tre­pre­neur­ial side of things af­ter spend­ing a com­bined eight years in BD roles at Mer­ck KGaA and Boehringer In­gel­heim: An ear­ly CEO of Cell­tech Bi­o­log­ics (ac­quired by Lon­za), he al­so helped cre­ate the com­pa­ny now known as Ver­nalis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER